{
    "clinical_study": {
        "@rank": "165049", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine the probability of engraftment with total body irradiation,\n      cyclophosphamide, fludarabine, and anti-thymocyte globulin followed by HLA nongenotypically\n      identical donor, T-cell depleted hematopoietic cell transplantation in patients with\n      Fanconi's anemia.\n\n      II.  Determine the incidence of acute and chronic graft-versus-host disease in these\n      patients after undergoing this treatment regimen.\n\n      III.  Determine the one-year survival rate in these patients after undergoing this treatment\n      regimen.\n\n      IV.  Determine the toxicity of this treatment regimen in these patients. V.  Determine the\n      incidence of relapse in patients with myelodysplastic syndrome or acute myeloid leukemia\n      after undergoing this treatment regimen."
        }, 
        "brief_title": "Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia", 
        "condition": "Fanconi's Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Fanconi Anemia", 
                "Fanconi Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Donor bone marrow, peripheral blood, or umbilical cord blood is processed\n      to harvest CD34+ cells.\n\n      Patients receive preparative cytoreductive therapy comprising total body irradiation on day\n      -6; cyclophosphamide IV over 2 hours on days -5 to -2; fludarabine IV over 30 minutes on\n      days -5 to -2; methylprednisone IV on days -5 to 24; anti-thymocyte globulin IV over 4-6\n      hours on days -5 to -1; cyclosporine IV over 2 hours every 12 hours (every 8 hours for\n      patients less than 40 kg in weight) on days -3 to 180, and then tapering in the absence of\n      graft-versus-host disease;  hematopoietic cell transplantation on day 0; and filgrastim\n      (G-CSF) IV starting on day 1 and continuing until blood counts recover.\n\n      Patients are followed at days 60, 90, and 180, and then annually for 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Patients with a diagnosis of Fanconi's anemia AND Aplastic anemia OR Myelodysplastic\n             syndrome OR Acute leukemia with or without chromosomal anomalies Aplastic anemia as\n             defined by having at least one of the following: Platelet count less than 20,000/mm3\n             Absolute neutrophil count less than 500/mm3 Hemoglobin less than 8 g/dL\n\n          -  Myelodysplastic syndrome with multilineage dysplasia With or without chromosomal\n             anomalies\n\n          -  Hematologic malignancy (e.g., acute myeloid leukemia, acute lymphoblastic leukemia,\n             or B-cell non-Hodgkin's lymphoma)\n\n          -  No greater than 30% blasts in bone marrow or greater than 5% blasts in peripheral\n             blood\n\n          -  No active CNS leukemia at time of transplantation\n\n          -  Must have an HLA A, B, DRB1 identical or 1 antigen mismatched related (nonsibling) or\n             unrelated bone marrow, peripheral blood, or umbilical cord blood donor\n\n        --Prior/Concurrent Therapy--\n\n          -  Radiotherapy: No prior radiotherapy that would preclude total body irradiation\n\n          -  Surgery: Not specified\n\n        --Patient Characteristics--\n\n          -  Performance status: Karnofsky 70-100% OR Lansky 50-100%\n\n          -  Hematopoietic: See Disease Characteristics\n\n          -  Hepatic: No hepatic failure (e.g., coagulopathy or ascites)\n\n          -  Renal: Creatinine clearance at least 40 mL/min\n\n          -  Cardiovascular: Ejection fraction at least 45%\n\n          -  Other: No active uncontrolled infection within one week of transplantation No\n             malignant solid tumor (e.g., squamous cell carcinoma of the head, neck, or cervix)\n             within 2 years of transplantation Not pregnant or nursing Negative pregnancy test\n             Fertile patients must use effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "34 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005898", 
            "org_study_id": "199/15109", 
            "secondary_id": [
                "UMN-MT-1999-05", 
                "UMN-MT9905"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "anti-thymocyte globulin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cyclosporine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "filgrastim", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "fludarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "methylprednisolone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antilymphocyte Serum", 
                "Cyclophosphamide", 
                "Cyclosporins", 
                "Cyclosporine", 
                "Fludarabine monophosphate", 
                "Lenograstim", 
                "Fludarabine", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "John E. Wagner, Jr.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005898"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2004"
    }, 
    "geocoordinates": {
        "University of Minnesota Cancer Center": "44.98 -93.264"
    }
}